Klotho Neurosciences Shares Surge 800% on Gene Therapy News
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Klotho Neurosciences Inc. (NASDAQ: KLTO) is a public biotechnology company headquartered in Omaha, Nebraska. The firm focuses on developing protein, cell, and gene therapies for age-related cognitive and neurodegenerative disorders. Originally incorporated as ANEW MEDICAL, the company officially changed its name and ticker symbol to Klotho Neurosciences on September 17, 2024, reflecting its emphasis on the secreted form of the Klotho gene (s-KL) for conditions such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease.
Corporate Structure and Experience
As of June 2025, Klotho Neurosciences operates with fewer than 10 employees, indicative of a lean, specialist-driven structure. The executive leadership includes:
- Dr. Joseph Sinkule, Founder and Chief Executive Officer, with over 40 years of drug and medical device research and development (R&D) and commercialization experience.
- Mr. Jeffrey LeBlanc, Chief Financial Officer, whose background includes investment management and venture financing.
- Dr. Bradford A. Navia, Chief Medical Advisor, a specialist in internal medicine and neurology with clinical development experience.
- Dr. Miguel Chillón Rodriguez, Chief Scientific Officer, inventor of the α-Klotho patents and head of gene therapy research at Universitat Autònoma de Barcelona.
- Dr. Shalom Hirschman, Medical Advisor, with a background in molecular biology and virology research.
Independent directors include Dr. Samuel Zentman, who has experience in corporate finance and technology governance, and Mr. Jon McGarity, a consultant with experience in the biotechnology sector.
Gene therapy by Sangharsh Lohakare
Developments and News
On March 28, 2024, the company participated in the 22nd Aesthetic and Anti-Aging Medicine World Congress in Monaco, presenting its s-KL gene therapy platform. On June 9, 2025, Klotho Neurosciences announced pre-clinical study results demonstrating that adeno-associated virus serotype 9 (AAV9) delivery of the secreted Klotho protein increased lifespan by 20% in animal models. Following this announcement, KLTO shares rose by approximately 800%. The company subsequently filed multiple Form 8-K reports on June 11, 13, and 16, 2025, disclosing material agreements, unregistered equity sales, and preparations for an Investigational New Drug (IND) application with the U.S. Food and Drug Administration.
Financial and Strategic Analysis
On June 30, 2025, KLTO shares closed at $1.12, marking a 55.53% gain for the day on a volume of 21.1 million shares. Key financial metrics for the trailing twelve months include:
| Metric | Value |
|---|---|
| Net Income | -$7.71 million |
| Diluted EPS | -$0.27 |
| Total Cash (Q1 2025) | $0.57 million |
| Total Debt/Equity (Q1 2025) | 276.8% |
| Levered Free Cash Flow (TTM) | -$1.95 million |
| Market Cap (intraday) | $54.2 million |
| 52-Week Range | $0.114 – $6.29 |
The company has no product revenues and relies on equity financing and collaborations to fund its R&D activities. Strategic priorities include advancing the s-KL gene therapy candidates through IND discussions for ALS and pursuing Alzheimer’s and Parkinson’s programs, alongside collaborations with research institutions.
Market Position and Industry Context
Klotho Neurosciences occupies an early-stage segment of the gene therapy market, with exclusive global rights to the secreted Klotho splice variant under patent in the U.S., Europe, and China. The company’s approach addresses high unmet medical needs in neurodegenerative disorders, but its path to commercialization requires successful clinical trials and regulatory approval. KLTO’s share price volatility reflects characteristics typical of many early-stage biotech firms, where value is often linked to development milestones instead of current revenues. While competition in Klotho gene-based therapies is limited, the company faces challenges from established pharmaceutical firms pursuing similar therapeutic areas.
tl;dr
On June 9, 2025, Klotho Neurosciences reported that AAV9-mediated delivery of the secreted Klotho protein extended lifespan by 20% in pre-clinical models, driving an 800% increase in KLTO shares. Subsequent SEC filings on June 11, 13, and 16, 2025, detailed material agreements and preparations for an IND submission in ALS. Trading at $1.12 on June 30, 2025, the company has no revenues, a negative cash flow profile, and a market cap near $54 million. Klotho Neurosciences aims to advance toward human trials in the second half of 2025 but will require additional capital to support development and regulatory processes.